ClinicalTrials.gg
RecruitingNCT07089251Updated Jul 28, 2025

The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery

A Phase 4 interventional study of low-dose epinephrine and tranexamic acid and Tranexamic Acid (TXA) treatment in Knee Arthroplasty, Total, Knee Arthritis, Osteoarthritis and Total Knee Anthroplasty, sponsored by King Abdullah International Medical Research Center. Recruiting at 1 site in Saudi Arabia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by King Abdullah International Medical Research Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing Tranexamic Acid in Osteoarthritis — 3 open to participants now, 3 under way, 1 of them phase 3. Tranexamic Acid · Osteoarthritis.

Planned enrollment
12th of 15
80 · median 149
Started
2025
the only one that year
Phase 4
6 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
King Abdullah International Medical Research Center

Among the 15 studies testing Tranexamic Acid in Osteoarthritis, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 4, and was the 14th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

3 of the 15 studies testing Tranexamic Acid in Osteoarthritis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing Tranexamic Acid in Osteoarthritis, or all of them as a file.
02

Study summary

The aim of this clinical trial is to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative blood loss, thromboembolic complications, and hospitalization duration in patients undergoing knee joint arthroplasty.

Also aim to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative thromboembolic complications, and hospitalization duration

Read the detailed description

Patients will be randomly divided into two groups: one receiving intravenous low-dose epinephrine and tranexamic acid, while the other will receive TXA alone as the control. Randomization to be done using a computer-generated table.

The study will be done a superiority clinical trial. with an estimated 24 hour blood loss of 300 ml, with standard deviation of 150 ml. a power of 80% and alpha 5%, an estimated sample size of 80 is needed to detect a difference.

03

Conditions studied

  • Knee Arthroplasty, Total
  • Knee Arthritis, Osteoarthritis
  • Total Knee Anthroplasty
  • Blood Loss
  • Tranexamic Acid Use
  • Epinephrine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing knee joint arthroplasty.
  • Saudi and Non-Saudi Patient.
  • Patients who have Complete medical record.

Exclusion criteria

Exclusion Criteria:

  • End stage renal disease
  • Liver cirrhosis
  • Coagulopathy
  • Pre-operative \<10 5.
  • History of cerebrovascular accident or myocardial infarction in past 12 months.
  • History of Heart failure.
  • History of arrhythmia.
  • History of pheochromocytoma, thyrotoxicosis and glaucoma.
  • Pregnancy or breast feeding
  • History of Deep venous thrombosis or pulmonary embolism
  • Allergy to epinephrine or tranexamic acid
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Epinephrine + Tranexamic Acid Group

    The experimental group will receive both epinephrine and tranexamic acid

    Drug: low-dose epinephrine and tranexamic acid

  • Active comparator
    Tranexamic Acid Group

    The comparator group will receive only tranexamic acid

    Drug: Tranexamic Acid (TXA) treatment

Interventions

06

What researchers measure

Primary outcomes

  1. Perioperative blood loss

    Calculated 24 h blood loss in mL, Hidden blood loss in mL, Hemoglobin levels in g/dL, Hematocrit levels as a percentage, Platelets count in cells/µL.

    Time frame: Daily, till post-operative day 5

Secondary outcomes

  1. Thromboembolic complications

    Time frame: Daily, till post-operative day 5

  2. Hospitalization duration

    Time frame: Daily, till post-operative day 5

  3. Drug side effects (epinephrine + tranexamic acid)

    Time frame: Daily, till post-operative day 5

  4. Complications

    VTE, SSI, UTI, AKI, Cardiac Arrhythmias, Stroke

    Time frame: Daily, till post-operative day 5

07

Study locations

1 of 1 sites recruiting
  • King Abdulaziz Medical City, Ministry of National Guard - Health Affairs
    Riyadh, Riyadh Region, Saudi Arabia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 23 months is below that.

Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 28, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Jun 24, 2027
CompletionEst.
Jun 24, 2027
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07089251
Lead sponsor
King Abdullah International Medical Research Center
Responsible party
Wazzan Saleh ALJuhani (Principal investigator, Orthopedic Surgeon, King Abdullah International Medical Research Center) — Principal investigator
First posted
Jul 28, 2025
Start date
Jul 15, 2025
Primary completion
Jun 24, 2027 (estimated)
Completion
Jun 24, 2027 (estimated)
Last update
Jul 28, 2025

Study contacts

Dr. Turki Althunayan
Contact
althunayan.tu@hotmail.com
+966 55 994 4782
Wazzan Aljuhani, MD, FRCSC, MBA, MMEd
principal investigator · King Abdulaziz Medical City, MNGHA

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epinephrine · Tranexamic Acid

Start the discussion